Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs McKesson Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while McKesson Corporation trades at $810.84 (market cap $94.36B). The key difference: McKesson Corporation is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and McKesson Corporation pays a 0.41% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MCK | |
|---|---|---|
Market Cap | $39.89B | $94.36B |
Sector | Health | Health |
52-Week High | $491.22 | $995.69 |
52-Week Low | $278.09 | $659.01 |
Enterprise Value | $38.15B | $99.00B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
McKesson (MCK) trades at $805.96, up 1.66% with strong bullish momentum near its pivot point of $799. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations, and revenue growth accelerating to $359.05B in 2025. Analyst sentiment is overwhelmingly positive with an 80% buy rating and a $932.83 consensus price target, while recent corporate developments include a strategic investment in Medical-Surgical Solutions with Apollo Funds.
The outlook remains favorable given robust cash flow generation and expanding profitability, though risks include policy uncertainties and high leverage. Upside potential is supported by valuation discounts relative to sector peers and continued execution in specialty pharma and oncology services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
